Showing Results for
- Academic Journals (1,966)
Search Results
- 1,966
Academic Journals
- 1,966
-
From:Pharmaceutical Technology Europe (Vol. 24, Issue 11) Peer-ReviewedA new report has forecast that the global biopharmaceutical market will be worth more than $320 billion by 2020, up from just $138 billion in 2011. According to global business intelligence firm G61 Research, annual...
-
From:MPR Pediatricians' Edition (Vol. 23, Issue 2)MenHibrix (meningococcal [Groups C and Y] and haemophilus b tetanus toxoid conjugate vaccine; GlaxoSmithKline) has been approved. MenHibrix is the first combination vaccine indicated to prevent invasive disease...
-
From:Regenerative Medicine (Vol. 7, Issue 4)Author(s): Marilyn Robertson 1 Stem cells & cardiovascular disease There are approximately 2000 open clinical trials involving stem cells shown on the Clinical Trials website [101] , of which a significant...
-
From:Pharmaceutical Technology Europe (Vol. 23, Issue 9) Peer-ReviewedA history of Innovation In 1897, Lonza was founded on the banks of the river Lonza in the Swiss Alps by adventurous entrepreneurs. Today Lonza continues to embody that pioneering spirit as a leading innovator and...
-
From:Pharmaceutical Technology Europe (Vol. 21, Issue 6) Peer-ReviewedA survey of UK life sciences companies conducted by the UK's Biolndustry Association (BIA) has revealed that many companies are finding it extremely difficult to access financing--partly because the sector is viewed as...
-
From:Applied Clinical Trials (Vol. 14, Issue 2) Peer-ReviewedOne-year data from a Biogen (Cambridge, MA) and Elan (San Diego, CA) Phase III trial of Antegren (natalizumab) met its primary endpoint for MS....
-
From:Research-Technology Management (Vol. 50, Issue 5) Peer-ReviewedThe Myth of the Bioteeh Revolution: An Assessment of Technological, Clinical and Organisational Change; Michael M. Hopkins, Paul A. Martin, Paul Nightingale, Alison Kraft, and Surya Mahdi; Research Policy, Max, 2007;...
-
From:Applied Clinical Trials (Vol. 14, Issue 1) Peer-ReviewedMedarex (Princeton, NJ) and Cell Genesys (South San Francisco, CA) began a Phase I trial for Medarex's antibody MDX-010 in combination with Cell Genesys' GVAX prostate cancer vaccine....
-
From:Applied Clinical Trials (Vol. 14, Issue 7) Peer-ReviewedGenentech's (South San Francisco, CA) Lucentis (ranibizumab) and verteporfin met its primary endpoint of maintained vision in wet AMD patients in a preliminary analysis of a Phase I/II trial, but it also showed an...
-
From:Applied Clinical Trials (Vol. 14, Issue 6) Peer-ReviewedCV Therapeutics (Palo Alto, CA) met its primary endpoint for a Phase III angina trial of Ranexa (ranolazine)....
-
From:Applied Clinical Trials (Vol. 14, Issue 7) Peer-ReviewedA Phase II trial showed that Biogen Idec's (Basel, Switzerland) galiximab combined with Rituxan (rituximab) worked better than Rituxan alone at treating relapsed or refractory non-Hodgkin's lymphoma....
-
From:Applied Clinical Trials (Vol. 15, Issue 2) Peer-ReviewedCell Genesys' (South San Francisco, CA) San Diego manufacturing operation has been acquired by Genzyme (Cambridge, MA)....
-
From:Applied Clinical Trials (Vol. 15, Issue 1) Peer-Reviewed* Preliminary results from a Phase II trial of Genentech's (South San Francisco, CA) Tarceva (erlotinib) plus Avastin (bevacizumab) showed the combination was similar to Avastin alone in treating kidney cancer....
-
From:Bulletin of the World Health Organization (Vol. 78, Issue 2) Peer-ReviewedAs more and more infectious agents become targets for immunization programmes, the spectrum of adverse events linked to vaccines has been widening. Although some of these links are tenuous, relatively little is known...
-
From:Management Review (Vol. 78, Issue 7) Peer-ReviewedBiotech Firms Seek Balance of Business And Science On April 13, 1988, a patent was issued to Harvard University for the world's first genetically engineered animal, a cancer-prone mouse. The event marked the beginning...
-
From:Pharmaceutical Technology Europe (Vol. 26, Issue 8) Peer-ReviewedAddress: Chaussee de Malines, 455 B-1950 Kraainem BELGIUM Date Founded: 1987 Telephone: +32 2 766 16 20 Fax: +32 2 766 16 39 E-mail: pharma@eurofins.com Website: www.Eurofins.com/Biopharma COMPANY...
-
From:Pharmaceutical Technology (Vol. 42, Issue 7) Peer-ReviewedSince the early days of biopharmaceutical manufacturing, upstream and downstream primary processing have been considered separate worlds. There was no profound reason for this separation, explains Charles Cooney,...
-
From:Pharmaceutical Technology Europe (Vol. 30, Issue 10) Peer-ReviewedSpecialist biopharmaceutical company, Alvotech, has announced receipt of a manufacturing license from the Icelandic Medicines Agency, applying to its biopharmaceutical facility based in Reykjavik, Iceland. Founded in...
-
From:American Medical Writers Association Journal (Vol. 34, Issue 1)Executives of medical writing departments share unique yet common concerns, needs, and perspectives and can benefit from engaging one another in an exchange of ideas and experiences. At its annual Medical Writing &...
-
From:Pharmaceutical Technology (Vol. 36, Issue 7) Peer-ReviewedLonza offers fully integrated end-to-end development and manufacturing for a wide range of technologies with Swiss quality performance and safety standards, strict containment and product segregation, and a focus on...